Carisma Therapeutics Inc. (CARM) — Cash Flow-to-Debt Ratio
Carisma Therapeutics Inc. (CARM) has a Cash Flow-to-Debt Ratio of 0.26x as of September 2025, meaning its operating cash flow of $1.91 Million could theoretically repay 0% of its total liabilities ($7.42 Million) in one year. See Carisma Therapeutics Inc. free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Carisma Therapeutics Inc. Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Carisma Therapeutics Inc. across 14 annual periods. Also explore Carisma Therapeutics Inc. equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Carisma Therapeutics Inc. (2011–2024)
Year-by-year debt coverage analysis for Carisma Therapeutics Inc.. For market capitalisation and broader financial context, see CARM market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.03x | $-59.92 Million | $58.37 Million | ▲ +20.3% |
| 2023 | -1.29x | $-81.18 Million | $63.02 Million | ▼ -3557.3% |
| 2022 | -0.04x | $-7.57 Million | $214.82 Million | ▲ +86.7% |
| 2021 | -0.26x | $-37.33 Million | $140.89 Million | ▼ -93.9% |
| 2020 | -0.14x | $-27.01 Million | $197.68 Million | ▲ +48.6% |
| 2019 | -0.27x | $-37.52 Million | $141.06 Million | ▲ +21.5% |
| 2018 | -0.34x | $-22.83 Million | $67.35 Million | ▼ -8.9% |
| 2017 | -0.31x | $-17.77 Million | $57.06 Million | ▼ -876.8% |
| 2016 | 0.04x | $2.62 Million | $65.42 Million | ▲ +102.1% |
| 2015 | -1.93x | $-34.53 Million | $17.88 Million | ▼ -19.7% |
| 2014 | -1.61x | $-29.31 Million | $18.17 Million | ▼ -6.3% |
| 2013 | -1.52x | $-13.49 Million | $8.89 Million | ▲ +70.1% |
| 2012 | -5.07x | $-19.09 Million | $3.76 Million | ▼ -31.2% |
| 2011 | -3.87x | $-10.87 Million | $2.81 Million | — |